New York, May 29, 2026, 16:04 (EDT)
AirSculpt Technologies shares dropped late Friday, underperforming other small caps, as the market waited for two June events where executives plan to argue the body-contouring business is back on track.
AirSculpt traded at $5.38, off 16 cents or 2.9%. Volume was near 423,000 shares, putting its market cap around $374 million. The iShares Russell 2000 ETF, often seen as a read on small caps, slipped about 0.7%.
AirSculpt isn’t coming up on an earnings report. The company said after Wednesday’s close it plans to speak at TD Cowen’s Future of the Consumer event in New York on June 3, and at Oppenheimer’s Consumer Growth & E-Commerce conference online June 9.
That counts now since the stock is moving less on new results and more on how well management backs up the early improvement it talked up earlier this month. AirSculpt operates branded sites offering minimally invasive fat removal and skin tightening. The business is now caught in the expanding weight-loss drug conversation.
Airsculpt Technologies, Inc. reported first-quarter revenue of $39.4 million on May 8, basically unchanged from last year. Case volume edged up 0.2%. Same-center sales improved 1%. CEO Yogi Jashnani called the quarter a “solid start to the year” and said same-center sales “continue to build.” The company kept its 2026 revenue forecast at $151 million to $157 million and sees adjusted EBITDA, excluding items like interest, taxes, depreciation and amortization, at $15 million to $17 million. Airsculpt Technologies, Inc.
Net loss came in at $2.4 million, better than $2.8 million last year. But adjusted EBITDA slipped to $3.3 million, down from $3.8 million. The numbers leave questions unanswered.
AirSculpt tapped equity markets this quarter, selling roughly 5.9 million shares in an at-the-market offering, according to a filing. The stock sales brought in about $14.6 million net. The company used around $11.4 million of that to pay down term-loan debt and finished March with $16.7 million in cash.
The backdrop for competition is mixed. Reuters said this month that Apyx Medical, InMode and AbbVie’s Allergan Aesthetics are chasing patients with loose skin or lost facial volume after fast weight loss. Apyx CEO Charles Goodwin said GLP-1 adoption is “one of the biggest new drivers.” InMode CEO Moshe Mizrahy said, “Long term, we believe it will help us.” BTIG analyst Sam Eiber told Reuters demand from these weight-loss patients could make up for “filler fatigue.” Reuters
The GLP-1 trend is a double-edged sword for AirSculpt. The company’s annual report said weight-loss drugs like these might help drive demand for body contouring and skin tightening. But AirSculpt also warned that drug-based and other non-surgical options could hit its prices, margins and share.
Uncertainty over next week’s pitch is in focus. If AirSculpt proves drug-driven weight loss is driving more patients to its body contouring business, investors might back its guidance. But if these drugs cut into demand for elective procedures or marketing and financing stay soft, Friday’s slip could point to deeper worries and not just be a blip.
